Literature DB >> 26156100

What has been overlooked on study of Chinese materia medica in the West?

Willow J H Liu1.   

Abstract

Chinese materia medica (CMM), including Chinese herbal, animal, and mineral medicine, has been widely researched in the past century for their biological and pharmacological activities. However, their mechanism and clinical efficacy studies did not always give expected results. For example, the most commonly used Chinese herb for menstrual disorders, Radix Angelicae sinensis, showed neither estrogenic nor progesteronic activity in laboratory and clinical studies. Its efficacy should not be denied simply based on such results, because it is mostly used together with other herbs in formulae. Moreover, its regulation on menstruation may take effect through other mechanisms, such as regulation of blood circulation. The key difference of Chinese medicine (CM) from conventional medicine is its unique holistic view on human body and diseases. CMM is mostly applied in clinic in the form of formulae. Study on individual CMM, simply using methods for development of conventional drugs, is unable to thoroughly reveal the power of CMM formulae. The reason may partly result from improper design due to the lack understanding about application principle of CMMs in CM, and/or to current lack of knowledge about the causes of some symptoms and diseases. This paper will introduce the importance of qi and blood in CM etiology and pathology, Zheng differentiation, formulation of CMMs, and explain why one formula can treat different diseases and one disease can be treated with different formulae. Examples in the paper will demonstrate that proper studies on Zheng and its corresponding clinically proven formulae could help scientists find new direction to explain and treat symptoms and diseases that so far modern medicine has been unable to, provided that the designer properly understands CM theories, etiology and pathology of CM, as well as modern medicine. Strategy suggestions about research methods for CMM and its formulae will be given at the end.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26156100     DOI: 10.1007/s11655-015-2081-x

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  29 in total

1.  Perspective: Herbal dangers.

Authors:  Masatomo Sakurai
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

2.  Perspective: The clinical trial barriers.

Authors:  Liang Liu; Elaine Lai-Han Leung; Xiaoying Tian
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

3.  Modernization: One step at a time.

Authors:  Zhiguo Xu
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

4.  Regulations: Herbal medicine rule book.

Authors:  Natasha Gilbert
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

Review 5.  Syndrome differentiation in modern research of traditional Chinese medicine.

Authors:  Miao Jiang; Cheng Lu; Chi Zhang; Jing Yang; Yong Tan; Aiping Lu; Kelvin Chan
Journal:  J Ethnopharmacol       Date:  2012-02-01       Impact factor: 4.360

6.  Introduction: the history of arsenic trioxide in cancer therapy.

Authors:  K H Antman
Journal:  Oncologist       Date:  2001

7.  Pharmacotherapeutic effects of kuei-chih-fu-ling-wan (keishi-bukuryo-gan) on human uterine myomas.

Authors:  S Sakamoto; H Yoshino; Y Shirahata; K Shimodairo; R Okamoto
Journal:  Am J Chin Med       Date:  1992       Impact factor: 4.667

8.  Comparative efficacy of Keishi-bukuryo-gan and pentoxifylline on RBC deformability in patients with "oketsu" syndrome.

Authors:  H Hikiami; H Goto; N Sekiya; N Hattori; I Sakakibara; Y Shimada; K Terasawa
Journal:  Phytomedicine       Date:  2003       Impact factor: 5.340

9.  Suppression of spontaneous development of uterine adenomyosis by a Chinese herbal medicine, keishi-bukuryo-gan, in mice.

Authors:  T Mori; S Sakamoto; T Singtripop; M K Park; T Kato; S Kawashima; H Nagasawa
Journal:  Planta Med       Date:  1993-08       Impact factor: 3.352

10.  Keishibukuryogan (gui-zhi-fu-ling-wan), a Kampo formula, decreases disease activity and soluble vascular adhesion molecule-1 in patients with rheumatoid arthritis.

Authors:  Kazuya Nozaki; Hiroaki Hikiami; Hirozo Goto; Takako Nakagawa; Naotoshi Shibahara; Yutaka Shimada
Journal:  Evid Based Complement Alternat Med       Date:  2006-09       Impact factor: 2.629

View more
  2 in total

1.  Jiangtang Xiaozhi Recipe () prevents diabetic retinopathy in streptozotocin-induced diabetic rats.

Authors:  Lin Li; Yan-Lin Li; Yun-Feng Zhou; Zheng-Yan Ge; Li-Li Wang; Zhi-Qiang Li; Yu-Jie Guo; Long Jin; Ye Ren; Jian-Xun Liu; Yang Xu
Journal:  Chin J Integr Med       Date:  2016-06-23       Impact factor: 1.978

2.  Effect of Guizhifulingwan (Keishibukuryogan) on climacteric syndrome: study protocol for a randomized controlled pilot trial.

Authors:  Jung-Eun Kim; Junghyo Cho; Ojin Kwon; Ae-Ran Kim; Hyo-Ju Park; So-Young Jung; Joo-Hee Kim; Mikyung Kim; Hye-Yoon Lee; Jun-Hwan Lee
Journal:  Trials       Date:  2017-03-21       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.